Showing results (111-120 of 148) with videos related to

Sort By:
Pageof 15
Cell Death and Differentiation|October 25, 2019
EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteinsLeah Fitzsimmons, Rachel Cartlidge, Catherine Chang, et al.
ACS Medicinal Chemistry Letters|December 21, 2017
Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain InhibitorsPhillip P Sharp, Jean-Marc Garnier, Tamas Hatfaludi, et al.
Blood|September 1, 2021
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLLPiers Blombery, Thomas E Lew, Michael A Dengler, et al.
Journal of Medicinal Chemistry|March 4, 2011
Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activityBrad E Sleebs, Peter E Czabotar, Wayne J Fairbrother, et al.
Blood Advances|December 15, 2022
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cellsCharis E Teh, Hongke Peng, Meng-Xiao Luo, et al.
Genes & Development|January 8, 2014
Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53Gemma L Kelly, Stephanie Grabow, Stefan P Glaser, et al.
Genome Medicine|April 15, 2021
PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signalingBing Yao, Tao Gui, Xiangwei Zeng, et al.
Cell Reports|November 29, 2018
The Mitochondrial Apoptotic Effectors BAX/BAK Activate Caspase-3 and -7 to Trigger NLRP3 Inflammasome and Caspase-8 Driven IL-1β ActivationJames E Vince, Dominic De Nardo, Wenqing Gao, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 17, 2015
Prosurvival Bcl-2 family members reveal a distinct apoptotic identity between conventional and plasmacytoid dendritic cellsEmma M Carrington, Jian-Guo Zhang, Robyn M Sutherland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2015
Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in OsteosarcomaAnkita Gupte, Emma K Baker, Soo-San Wan, et al.
Pageof 15